Recordati Rare Diseases appoints the FarmaMondo Group as the exclusive commercial partner for its orphan therapies Cosmegen®, Pedea® and Carbaglu® in Hong Kong. Under the
FarmaMondo Group CEO, Yaron Spigel, visited our Singapore office for a business review. After two years of virtual meetings due to the COVID restrictions, finally
FarmaMondo @Expopharm in Munich The FarmaMondo’s team took part in the Expopharm congress last week in Munich. After dozens of incredible meetings with our trusted
Qarziba® is an anti-GD2 monoclonal antibody that has shown to improve significantly the event-free and overall survival in children with high-risk neuroblastoma, with an acceptable safety profile.
FarmaMondo represents an innovative worldwide drug for the treatment of advanced neuroblastoma and is proud to announce its distribution also in Chile.
Molteni Farmaceutici and the FarmaMondo Group signed an exclusive marketing and distribution agreement for certain Molteni’s products of its pain and addiction management portfolio in
Amryt Pharma and the FarmaMondo Group signed an exclusive partnership agreement for the orphan disease innovative therapies Myalept®, Lojuxta® in the APAC region.
We use cookies that are strictly necessary to operate this website.
We also use optional cookies to improve your accessibility to our website and its functionality, to analyse and track your use of our website and to give you the best possible user experience.
You will need to activate optional cookies. For more detailed information on our use of cookies on this website, please read our Cookie Policy, which also explains how to customise your Cookies settings.
You can also accept all our cookies or customise your Cookies settings by clicking on the buttons provided below.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.